Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neurodevelopmental Disorders

ClinicalTrials.gov lists 5,562 trials for Neurodevelopmental Disorders or a narrower condition beneath it.

MeSH D065886 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 206 Phase 1/2 Phase 1/2 78 Phase 2 Phase 2 406 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 331 Phase 4 Phase 4 288 Not applicable Not applicable 3,042 Observational Observational 1,144 Phase 1 Phase 1 206 Phase 1/2 Phase 1/2 78 Phase 2 Phase 2 406 Phase 2/3 Phase 2/3 63 Phase 3 Phase 3 331 Phase 4 Phase 4 288 Not applicable Not applicable 3,042 Observational Observational 1,144

Trials per phase (log scale)

2 more sections with rows

340 of the 5,562 trials are tagged with Neurodevelopmental Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Neurodevelopmental Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neurodevelopmental Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 17 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 431

1990: 2 trials (Observational 2) 1991: 2 trials (Observational 1, Not applicable 1) 1992: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 1993: 3 trials (Phase 3 1, Phase 2 2) 1994: 2 trials (Not applicable 1, Phase 3 1) 1995: 2 trials (Observational 1, Not applicable 1) 1996: 6 trials (Observational 4, Phase 3 2) 1997: 12 trials (Observational 3, Phase 4 3, Phase 3 5, Phase 2 1) 1998: 10 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 1/2 1, Phase 1 1) 1999: 16 trials (Observational 6, Not applicable 2, Phase 4 2, Phase 3 6) 2000: 16 trials (Observational 7, Not applicable 5, Phase 3 2, Phase 2 1, Phase 1/2 1) 2001: 22 trials (Observational 8, Not applicable 5, Phase 4 2, Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 2) 2002: 34 trials (Observational 13, Not applicable 3, Phase 4 5, Phase 3 6, Phase 2 5, Phase 1 2) 2003: 44 trials (Observational 7, Not applicable 8, Phase 4 11, Phase 3 8, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2004: 70 trials (Observational 11, Not applicable 6, Phase 4 15, Phase 3 20, Phase 2/3 4, Phase 2 11, Phase 1/2 2, Phase 1 1) 2005: 93 trials (Observational 14, Not applicable 17, Phase 4 18, Phase 3 17, Phase 2/3 3, Phase 2 19, Phase 1/2 2, Phase 1 3) 2006: 102 trials (Observational 18, Not applicable 31, Phase 4 15, Phase 3 16, Phase 2 14, Phase 1/2 4, Phase 1 4) 2007: 112 trials (Observational 27, Not applicable 26, Phase 4 15, Phase 3 17, Phase 2/3 3, Phase 2 15, Phase 1/2 3, Phase 1 6) 2008: 125 trials (Observational 23, Not applicable 30, Phase 4 24, Phase 3 16, Phase 2/3 3, Phase 2 21, Phase 1/2 3, Phase 1 5) 2009: 144 trials (Observational 29, Not applicable 50, Phase 4 19, Phase 3 14, Phase 2/3 4, Phase 2 13, Phase 1/2 4, Phase 1 11) 2010: 140 trials (Observational 37, Not applicable 42, Phase 4 15, Phase 3 13, Phase 2/3 4, Phase 2 17, Phase 1/2 4, Phase 1 8) 2011: 137 trials (Observational 29, Not applicable 41, Phase 4 10, Phase 3 20, Phase 2/3 1, Phase 2 22, Phase 1/2 4, Phase 1 10) 2012: 168 trials (Observational 31, Not applicable 78, Phase 4 11, Phase 3 12, Phase 2/3 4, Phase 2 23, Phase 1/2 3, Phase 1 6) 2013: 169 trials (Observational 31, Not applicable 81, Phase 4 13, Phase 3 10, Phase 2/3 1, Phase 2 17, Phase 1/2 4, Phase 1 12) 2014: 223 trials (Observational 46, Not applicable 112, Phase 4 11, Phase 3 9, Phase 2/3 4, Phase 2 24, Phase 1/2 8, Phase 1 9) 2015: 213 trials (Observational 42, Not applicable 117, Phase 4 8, Phase 3 17, Phase 2/3 3, Phase 2 12, Phase 1/2 5, Phase 1 9) 2016: 257 trials (Observational 41, Not applicable 154, Phase 4 12, Phase 3 8, Phase 2/3 4, Phase 2 21, Phase 1/2 3, Phase 1 14) 2017: 208 trials (Observational 46, Not applicable 119, Phase 4 7, Phase 3 14, Phase 2 12, Phase 1/2 1, Phase 1 9) 2018: 306 trials (Observational 69, Not applicable 171, Phase 4 13, Phase 3 16, Phase 2/3 4, Phase 2 22, Phase 1/2 3, Phase 1 8) 2019: 301 trials (Observational 72, Not applicable 176, Phase 4 8, Phase 3 11, Phase 2 18, Phase 1/2 3, Phase 1 13) 2020: 249 trials (Other 1, Observational 60, Not applicable 149, Phase 4 7, Phase 3 6, Phase 2 15, Phase 1/2 2, Phase 1 9) 2021: 349 trials (Observational 76, Not applicable 231, Phase 4 8, Phase 3 5, Phase 2/3 4, Phase 2 15, Phase 1/2 1, Phase 1 9) 2022: 361 trials (Observational 68, Not applicable 255, Phase 4 4, Phase 3 6, Phase 2/3 2, Phase 2 18, Phase 1 8) 2023: 431 trials (Observational 84, Not applicable 300, Phase 4 6, Phase 3 10, Phase 2/3 4, Phase 2 13, Phase 1/2 3, Phase 1 11) 2024: 425 trials (Observational 74, Not applicable 298, Phase 4 6, Phase 3 8, Phase 2/3 4, Phase 2 20, Phase 1/2 2, Phase 1 13) 2025: 392 trials (Observational 84, Not applicable 266, Phase 4 5, Phase 3 8, Phase 2/3 2, Phase 2 16, Phase 1/2 4, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 367
2025 392
2024 425
2023 431
2022 361
2021 349
2020 249
2019 301
2018 306
2017 208

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 430 trials starting in 2026 and about 410 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 564 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 3,332 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neurodevelopmental Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 206
Phase 1/2 78
Phase 2 406
Phase 2/3 63
Phase 3 331
Phase 4 288
Not applicable 3,042
Observational 1,144
Expanded access 3
Unknown 1

How many Neurodevelopmental Disorders trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 270
Recruiting 738
Enrolling by invitation 82
Active, not recruiting 183
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neurodevelopmental Disorders trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Eli Lilly and Company 53
National Institute of Mental Health (NIMH) 53
Shire 48

Which drugs are being tested for Neurodevelopmental Disorders? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
METHYLPHENIDATE 186
Lisdexamfetamine Dimesylate 51
Aripiprazole 37

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Atomoxetine arm 104
Treatment As Usual 75
IR Risperidone 28
Control (placebo) group 24
Transcranial Magnetic Stimulation 24

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neurodevelopmental Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Suicidal ideation 69 22
Patent ductus arteriosus 42 1
Appendicitis 41 23
Bronchopulmonary Dysplasia 37 1
Aggression 36 16

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neurodevelopmental Disorders? (305)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Examining tolerability, safety, and blinding in 1032 transcranial electrical stimulation sessions for children and adolescents with neuropsychiatric and neurodevelopmental disorders. Scientific reports 2025 Yes
Genotypic, functional, and phenotypic characterization in CTNNB1 neurodevelopmental syndrome. HGG advances 2025 Yes
Link between neurodevelopmental disorders and suicidal risk in children. L'Encephale 2025 Yes
Bronchopulmonary dysplasia to predict neurodevelopmental impairment in infants born extremely preterm. Pediatric research 2025 Yes
Association of a Count of Inpatient Morbidities with 2-Year Outcomes among Infants Born Extremely Preterm. The Journal of pediatrics 2025 Yes

Showing 5 of 305 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (14)

MeSH descendants one level down with at least one trial, most trials first.

+4 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages